BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20337821)

  • 1. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
    Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib-induced lupus erythematosus tumidus.
    Böckle BC; Baltaci M; Weyrer W; Sepp NT
    Oncologist; 2009 Jun; 14(6):637-9. PubMed ID: 19474161
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib-induced cutaneous lupus in a patient with myeloma.
    Heelan K; McKenna DB
    J Dermatol; 2013 Feb; 40(2):123-4. PubMed ID: 23078265
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
    Yokose N; Hirakawa T; Inokuchi K
    Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
    Obeid KM; Ferrara R; Sharma M
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib-related diffuse alveolar hemorrhage.
    Wirk B
    J Clin Oncol; 2012 Dec; 30(36):e379-81. PubMed ID: 23150703
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib.
    Tariman JD; Lemoine C
    Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
    He Q; Zhao X; He Y; Tan D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous bortezomib: a step towards optimised drug use.
    Mateos MV
    Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib-induced acute pancreatitis.
    Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
    JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
    Connolly G
    Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety and efficacy of bortezomib in relapsed multiple myeloma.
    Jagannath S
    Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Dun X; Yuan Z; Fu W; Zhang C; Hou J
    Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.